

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1201	Application No. 09/436,347
	Applicant(s): Christine A. WHITE et al.	Examiner: Alana M. Harris
	Filing Date: November 9, 1999	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
anh	A1	5,736,137	04/07/1998	Anderson, et al.			
	A2	5,776,456	07/07/1998	Anderson, et al.			
	A3	5,843,439	12/01/1998	Anderson, et al.			
	A4	6,399,061	06/04/2002	Anderson, et al.			
	A5	6,682,734	01/27/2004	Anderson, et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

anh	B1	McLaughlin, P. et al. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program." Journal of Clinical Oncology, Vol. 16, No. 8. August 1998, pp. 2825-2833.

EXAMINER <i>anh</i>	DATE CONSIDERED 11/23/2005
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 1